This is the load-bearing longevity claim that distinguishes Bogomolets’s programme from the wider body of mid-century immunology and tissue-therapy work, which it otherwise resembles. The claim is stated in his English monograph The Prolongation of Life (Duell, Sloan and Pearce, 1946) and is the framing he carried into Soviet state-sponsored promotion of ACS in the 1930s and 1940s. The ‘past one hundred, perhaps one hundred and fifty’ wording is reproduced verbatim from Joe Schwarcz’s 20 September 2024 summary at McGill OSS, which gives it as a direct paraphrase of the monograph. The claim is classified as untested at its hard endpoint: no controlled outcome trial has ever measured a lifespan effect of ACS in humans, so the maximum-lifespan claim has not been formally refuted by a clinical trial. The late-1940s Western evaluation of ACS in 3,500 patients reported by Schwarcz concluded that the serum ‘is not a cure for anything’ across the disease indications it was tested for, but did not study maximum lifespan as an endpoint. Bogomolets himself died in 1946 at age 65 (birth-death dates anchored against PMID 13382647 and the English Wikipedia infobox), well short of the figure he had promised, but his exposure to ACS is not established by this bundle and his personal mortality is therefore biographical context rather than the kind of treated-cohort lifespan endpoint that would formally refute the claim.